|
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITINGN/ASponsored by Memorial Sloan Kettering Cancer Center
Actively Recruiting
PhaseN/A
SponsorMemorial Sloan Kettering Cancer Center
Started2023-07-03
Est. completion2028-07-03
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →
NCT05940272
Summary
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:
Providers
* Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)
Patients
* Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
* Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
* Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
* Self-identify as Black and/or White
* Per medical record, 18 years of age or older
* Per self-report, fluent in English\*\*
* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
2. What is your preferred language for healthcare? (must respond English)
Exclusion Criteria:
Providers
* Per self-report, planning to leave the cancer center in the next 12 months
Patients
* Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
* Per research staff judgment and/or self-report, too ill or weak to complete study procedures
* Per medical record or self-report, receiving hospice care at the time of enrollmentConditions7
CancerDLBCL - Diffuse Large B Cell LymphomaLarge B-cell LymphomaLarge-cell LymphomaLymphomaLymphoma, B-CellMediastinal B-Cell Diffuse Large Cell Lymphoma
Locations2 sites
Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, New York, 10065
Kelly McConnell, PhD646-888-0026
NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)
New York, New York, 10065
Alan Astrow, MD646-962-2330
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorMemorial Sloan Kettering Cancer Center
Started2023-07-03
Est. completion2028-07-03
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →
NCT05940272